300 related articles for article (PubMed ID: 27067724)
1. Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia.
Rajagopalan K; Trueman D; Crowe L; Squirrell D; Loebel A
Pharmacoeconomics; 2016 Jul; 34(7):709-21. PubMed ID: 27067724
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of lurasidone vs aripiprazole among patients with schizophrenia who have previously failed on an atypical antipsychotic: an indirect comparison of outcomes from clinical trial data.
Rajagopalan K; Hassan M; O'Day K; Meyer K; Grossman F
J Med Econ; 2013 Jul; 16(7):951-61. PubMed ID: 23701260
[TBL] [Abstract][Full Text] [Related]
3. Cost-utility analysis of lurasidone for the first-line treatment of schizophrenia in China.
Liu J; Cao L; Wu J
Front Public Health; 2022; 10():987408. PubMed ID: 36187655
[TBL] [Abstract][Full Text] [Related]
4. Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France.
Druais S; Doutriaux A; Cognet M; Godet A; Lançon C; Levy P; Samalin L; Guillon P
Pharmacoeconomics; 2016 Apr; 34(4):363-91. PubMed ID: 26883132
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK.
Tempest M; Sapin C; Beillat M; Robinson P; Treur M
J Ment Health Policy Econ; 2015 Dec; 18(4):185-200. PubMed ID: 26729007
[TBL] [Abstract][Full Text] [Related]
6. [Comparison of medical and economic benefits of antipsychotics in the treatment of schizophrenia in France].
Druais S; Doutriaux A; Cognet M; Godet A; Lançon C; Levy P; Samalin L; Guillon P
Encephale; 2017 Aug; 43(4):311-320. PubMed ID: 27623123
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of olanzapine in the first-line treatment of schizophrenia in China.
Zhao J; Jiang K; Li Q; Zhang Y; Cheng Y; Lin Z; Xuan J
J Med Econ; 2019 May; 22(5):439-446. PubMed ID: 30732487
[TBL] [Abstract][Full Text] [Related]
8. Hospitalization risk in patients with schizophrenia treated with dose-equivalent antipsychotics.
Ng-Mak D; Messali A; Huang A; Wang L; Loebel A
Am J Manag Care; 2019 Jul; 25(14 Suppl):S279-S286. PubMed ID: 31365818
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of atypical antipsychotics for the management of schizophrenia in the UK .
Davies A; Vardeva K; Loze JY; L'italien GJ; Sennfalt K; Baardewijk Mv
Curr Med Res Opin; 2008 Nov; 24(11):3275-85. PubMed ID: 18947458
[TBL] [Abstract][Full Text] [Related]
10. Real-world adherence assessment of lurasidone and other oral atypical antipsychotics among patients with schizophrenia: an administrative claims analysis.
Rajagopalan K; Wade S; Meyer N; Loebel A
Curr Med Res Opin; 2017 May; 33(5):813-820. PubMed ID: 28098496
[TBL] [Abstract][Full Text] [Related]
11. Cost analysis of lurasidone for the treatment of schizophrenia in adolescents and adults within the United Kingdom.
Dymond A; Afonso D; Green W
BMC Health Serv Res; 2022 Aug; 22(1):1084. PubMed ID: 36002828
[TBL] [Abstract][Full Text] [Related]
12. Cost of Relapse Management in Patients with Schizophrenia in Italy and Spain: Comparison Between Lurasidone and Quetiapine XR.
Restelli U; García-Goñi M; Lew-Starowicz M; Mierzejewski P; Silvola S; Mayoral-van Son J; Croce D; Rocca P; Crespo-Facorro B
Clin Drug Investig; 2020 Sep; 40(9):861-871. PubMed ID: 32648201
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of lurasidone vs quetiapine extended-release (XR) in patients with bipolar depression.
Rajagopalan K; Meyer K; O'Day K; Denno M; Loebel A
J Med Econ; 2015; 18(10):821-7. PubMed ID: 25985265
[TBL] [Abstract][Full Text] [Related]
14. Health Care Utilization and Treatment Persistence Associated with Oral Paliperidone and Lurasidone in Schizophrenia Treatment.
Jiang Y; Ni W
J Manag Care Spec Pharm; 2015 Sep; 21(9):780-92. PubMed ID: 26308225
[TBL] [Abstract][Full Text] [Related]
15. Annual cost of relapses and relapse-related hospitalizations in adults with schizophrenia: results from a 12-month, double-blind, comparative study of lurasidone vs quetiapine extended-release.
Rajagopalan K; O'Day K; Meyer K; Pikalov A; Loebel A
J Med Econ; 2013 Aug; 16(8):987-96. PubMed ID: 23742620
[TBL] [Abstract][Full Text] [Related]
16. Long-term cost-effectiveness of atypical antipsychotics in the treatment of adults with schizophrenia in the US.
O'Day K; Rajagopalan K; Meyer K; Pikalov A; Loebel A
Clinicoecon Outcomes Res; 2013; 5():459-70. PubMed ID: 24049452
[TBL] [Abstract][Full Text] [Related]
17. Cost effectiveness of paliperidone palmitate for the treatment of schizophrenia in Germany.
Zeidler J; Mahlich J; Greiner W; Heres S
Appl Health Econ Health Policy; 2013 Oct; 11(5):509-21. PubMed ID: 23975630
[TBL] [Abstract][Full Text] [Related]
18. Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Sweden.
Mehnert A; Nicholl D; Pudas H; Martin M; McGuire A
J Med Econ; 2012; 15(5):844-61. PubMed ID: 22458756
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of aripiprazole orally disintegrating tablets in the treatment of schizophrenia in China.
Lin Z; Xuan J
Expert Rev Pharmacoecon Outcomes Res; 2020 Oct; 20(5):549-557. PubMed ID: 32757968
[TBL] [Abstract][Full Text] [Related]
20. Long-term health-related quality of life improvements among patients treated with lurasidone: results from the open-label extension of a switch trial in schizophrenia.
Awad G; Ng-Mak D; Rajagopalan K; Hsu J; Pikalov A; Loebel A
BMC Psychiatry; 2016 Jun; 16():176. PubMed ID: 27245981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
